Emicizumab does not interfere with the activated clotting time-Reference-Cited by-同舟云学术

Emicizumab does not interfere with the activated clotting time

Published:2022-01-21 Issue:2 Volume:28 Page:362-366
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Capdevila Ladislas¹,Frère Corinne²³,Desvages Maximilien¹⁴,Harroche Annie⁵,Bally Cécile⁵,Abbes Ahmed⁶,d'Oiron Roseline⁴⁷^ORCID,Frenzel Laurent⁵^ORCID,Borgel Delphine¹⁴,Lasne Dominique¹⁴^ORCID

Affiliation:

1. Haematology Laboratory AP‐HP Hôpital Universitaire Necker‐Enfants Malades Paris France

2. INSERM UMRS_1166 Institute of Cardiometabolism and Nutrition Sorbonne Université Paris France

3. Haematology Laboratory AP‐HP Hôpital Universitaire Pitié‐Salpêtrière Paris France

4. HITh, UMR_S 1176 INSERM Université Paris‐Saclay Le Kremlin‐Bicetre France

5. Centre de Traitement de l'Hemophilie AP‐HP Hôpital Universitaire Necker‐Enfants Malades Paris France

6. GRC 29; Department of Anaesthesiology and Critical Care Medicine AP‐HP Sorbonne Université Hôpital Universitaire Pitié‐Salpêtrière Paris France

7. Service d'hématologie AP‐HP Hôpital de Bicêtre Le Kremlin‐Bicêtre France

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14497

Reference17 articles.

1. Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey

2. Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring

3. Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra®): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)

4. Effects of emicizumab on APTT, one‐stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors

5. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab as a Promising Form of Therapy for Type A Hemophilia - AReview of Current Knowledge from Clinical Trials;Current Protein & Peptide Science;2024-11

2. Effect of emicizumab on activated clotting time performed on i‐STAT Alinity analyzer;International Journal of Laboratory Hematology;2024-07-18